Drug Profile
GSK 1399686
Alternative Names: 1399686; GSK1399686Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Irritable bowel syndrome therapies
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ulcerative colitis
Most Recent Events
- 31 Jul 2012 GlaxoSmithKline completes a phase II trial in Ulcerative colitis in Belgium, Canada, Germany, Norway, and Sweden (NCT01036022)